BRAF and cancer: The Central America and Caribbean consensus on the management of mCRC recommended a first-line doublet (FOLFOX or FOLFIRI) or triplet (FOLFOXIRI) with an anti-VEGF antibody for patients with BRAF-mutated non-resectable cancer and for whom debulking surgery can be objective [58].